VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalinGlobeNewsWire • 03/30/21
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritusGlobeNewsWire • 03/08/21
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritusBusiness Wire • 03/08/21
Cara Therapeutics, Inc.'s (CARA) CEO Derek Chalmers on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 02/25/21
Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021GlobeNewsWire • 02/18/21
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/18/21
Are Options Traders Betting on a Big Move in Cara Therapeutics (CARA) Stock?Zacks Investment Research • 01/08/21
Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/21
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe PruritusGlobeNewsWire • 12/28/20
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe PruritusGlobeNewsWire • 12/02/20
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020GlobeNewsWire • 11/02/20
Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020GlobeNewsWire • 10/21/20
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritusGlobeNewsWire • 10/20/20
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritusBusiness Wire • 10/20/20